Table 2.
Baseline demographics/etiologies between total sample and study sample.
| Sample population (n = 1841) | Sample with ≥2 VAS reduction at 7 days (n = 1143) | Sample with <2 VAS reduction at 7 days (n = 698) | Sample with ≥2 VAS reduction at 7 days + “definitely purchase” (n = 682) | Sample with ≥2 VAS reduction at 7-days + “not definitely purchase” (n = 461) | Study sample (n = 240) | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age (years) | 55.6 | 54.4 | 54.3 | 56.4 | 56.3 | 57.9 |
| Duration of pain (years) | 6.4 | 6.5 | 6.2 | 6.4 | 6.6 | 6.5 |
| Women | 66% | 70% | 61% | 71% | 69% | 70% |
| Pain > than 6 months | 89% | 89% | 88% | 90% | 88% | 91% |
| Baseline VAS | 8.02 | 8.17 | 7.77 | 8.26 | 8.02 | 8.23 |
| 7-day treatment VAS | 5.03 | 3.38 | 7.72 | 2.97 | 3.97 | 2.82 |
| % pain reduction | 33% | 59% | 0% | 64% | 51% | 66% |
| VAS ≥2 reduction | 62% | 100% | 0% | 100% | 100% | 100% |
| VAS ≥3 reduction | 54% | 87% | 0% | 94% | 77% | 97% |
| % “definitely purchase” intent | 38% | 60% | 3% | 100% | 0% | 100% |
| Pain etiology | ||||||
| Osteoarthritis | 30% | 31% | 28% | 33% | 26% | 25% |
| Rheumatoid arthritis | 15% | 15% | 14% | 15% | 15% | 7% |
| Fibromyalgia | 10% | 10% | 9% | 10% | 11% | 20% |
| Sports injury | 8% | 8% | 7% | 8% | 8% | 12% |
| Neuropathy | 5% | 5% | 5% | 5% | 5% | 8% |
| Surgery | 6% | 6% | 5% | 6% | 6% | 6% |
| Tendinitis | 3% | 3% | 3% | 3% | 2% | 4% |
| Other | 23% | 22% | 29% | 20% | 27% | 18% |
Subjects often reported pain in multiple areas of the body, but this designation was predominantly for the back (49%), followed by knee (27%), shoulder (17%), hip (16%), neck (8%), and others (11%). The rank ordering of the locations where the PSWT medical device was applied mirrored the rank order of reported locations of pain.